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Hyperpolarized 13C Magnetic Resonance Imaging of
Fumarate Metabolism by Parahydrogen-induced
Polarization: A Proof-of-Concept in vivo Study
Neil J. Stewart,[a] Hitomi Nakano,[a] Shuto Sugai,[a] Mitsushi Tomohiro,[a] Yuki Kase,[a]
Yoshiki Uchio,[a] Toru Yamaguchi,[b] Yujirou Matsuo,[b] Tatsuya Naganuma,[c]
Norihiko Takeda,[d] Ikuya Nishimura,[a] Hiroshi Hirata,[a] Takuya Hashimoto,*[e] and
Shingo Matsumoto*[a]
Hyperpolarized [1-13C]fumarate is a promising magnetic reso-
nance imaging (MRI) biomarker for cellular necrosis, which plays
an important role in various disease and cancerous pathological
processes. To demonstrate the feasibility of MRI of [1-13C]
fumarate metabolism using parahydrogen-induced polarization
(PHIP), a low-cost alternative to dissolution dynamic nuclear
polarization (dDNP), a cost-effective and high-yield synthetic
pathway of hydrogenation precursor [1-13C]
acetylenedicarboxylate (ADC) was developed. The trans-selectiv-
ity of the hydrogenation reaction of ADC using a ruthenium-
based catalyst was elucidated employing density functional
theory (DFT) simulations. A simple PHIP set-up was used to
generate hyperpolarized [1-13C]fumarate at sufficient 13C polar-
ization for ex vivo detection of hyperpolarized 13C malate
metabolized from fumarate in murine liver tissue homogenates,
and in vivo 13C MR spectroscopy and imaging in a murine model
of acetaminophen-induced hepatitis.
1. Introduction
Cell death is a hallmark of various diseases including renal,
hepatic and myocardial injury, stroke and Alzheimer’s disease,
and furthermore plays an important role in cancer development
and treatment response.[1] There is an unmet medical need for
non-invasive, quantitative imaging techniques to assess the
spatial extent of pathological cell death and thus enable
personalization of treatments. While small-molecule positron
emission tomography (PET) probes have been proposed for
imaging apoptosis (programmed cell death),[2] the most
common type of cell death in various diseases is necrosis
(unregulated cell death), for which there are no clinically-
available imaging methods.
The advent of hyperpolarization of 13C (or 15N) nuclei in
biologically-relevant molecules by dissolution dynamic nuclear
polarization (dDNP)[3] has enabled molecular MRI as a means to
interrogate metabolism and other cellular processes with an
unprecedented sensitivity.[4–6] In particular, hyperpolarized (HP)
[1-13C]pyruvate and its conversion to lactate are exquisitely
sensitive to the Warburg effect; regulation of glycolytic
metabolism in cancerous cells,[7–9] with added specificity over
18F-fluorodeoxyglucose (FDG) PET.[10] In recent years, the devel-
opment of sterile, clinical-scale dDNP polarizers[11] has enabled
the realization of clinical application in humans.[5,6,12–14] In
seminal work, Gallagher and colleagues demonstrated that
[1,4-13C2]fumarate can also be hyperpolarized by dDNP, and that
the metabolic conversion of HP [1,4-13C2]fumarate to [1,4-
13C2]
malate can serve as a non-invasive imaging biomarker for
necrotic cell death.[15] The production of HP [1,4-13C2]malate has
been shown to be a sensitive biomarker to treatment response
in tumors,[15–17] and allow early detection of necrosis due to
acute kidney injury[18] and myocardial infarction.[19] HP 13C
fumarate possesses several desirable properties for application
as a necrosis probe in vivo; (i) fumarate is an endogenous
molecule and is thus biologically safe, (ii) its enzymatic
conversion to malate by a fumarase does not require any co-
factors, (iii) exogenously-delivered HP 13C fumarate does not (or
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very slowly) permeate(s) into healthy cells in which fumarase is
present, (iv) upon necrotic loss of cell plasma membrane
integrity, fumarase is released into the extracellular space. Thus,
in healthy cells no HP 13C malate is produced while in necrotic
cells HP 13C malate is produced in the extracellular space
without co-factors. As such, HP 13C malate production is a
sensitive marker of cell necrosis.
State-of-the-art dDNP equipment for the production of
sterile metabolic imaging probes is costly, and high clinical
throughput is constrained by long polarization build-up times
(~hours).
Parahydrogen-induced polarization (PHIP)-wherein the nat-
ural spin order of parahydrogen is utilized to generate hyper-
polarized 1H on a substrate molecule by hydrogenation[20,21] and
subsequently transfer polarization to a heteronucleus (X=13C,
15N etc.)[22]-may offer a cost-effective alternative. Apparatus is
relatively cost-effective and polarization times are rapid (~
seconds)[23] in comparison to dDNP. However, in conventional
“hydrogenative” PHIP, the requirement of an unsaturated
carbon-carbon bond on the substrate for hydrogenation
constrains the available substrate structure. As a result, until
recently, only a small number of biologically-relevant molecules
had been polarized by PHIP for in vivo HP 13C MRI studies,
including; hydroxyethyl [1-13C]propionate (HEP) to probe
angiography,[22,24,25] and [1-13C]succinate[26–28] and diethyl [1-13C]
succinate,[26,29] which are involved in Krebs cycle metabolism. A
means to overcome the substrate structure limitation was
proposed by Reineri et al, who demonstrated that by para-
hydrogen addition to an unsaturated ester precursor of the
target molecular probe, spin polarization transfer from 1H to the
carbonyl 13C and subsequent hydrolysis to cleave the “side-arm”
of the ester, the target HP imaging probe can be extracted in
the aqueous phase for in vivo MR applications. This PHIP side-
arm hydrogenation (PHIP-SAH) method has enabled the
unprecedented generation of HP [1-13C]pyruvate and
acetate[30,31] and the first in vivo studies with this technique.[32]
While a PHIP-SAH-suitable ester precursor of fumarate is yet
to be reported, parallel progress in catalyst chemistry is opening
up new avenues for PHIP substrates. The Rh-based catalysts-
typically of the form [Rh(diene)diphos]+ where diphos is a
chelating phosphine-that are most-widely used in hydrogena-
tive PHIP experiments are cis selective; tending to yield a cis
isomer as a hydrogenation product. For example, addition of
parahydrogen to acetylenedicarboxylate (ADC) yields
maleate,[28,33] the cis-isomer of butenedioate. Fumarate on the
other hand, is the trans-isomer of butenedioate. It was recently
demonstrated that commercially available ruthenium-based
catalysts can be used to generate HP [1-13C]fumarate by trans-
selective hydrogenation of [1-13C]ADC.[34,35] This relies on the
trans-stereoselectivity of these ruthenium-based catalysts[36,37]
and builds upon early PHIP work on Cp*Ru (Cp*: pentameth-
ylcyclopentadienyl) catalysts.[38] The chemistry is complex and
the addition of the reducing agent sodium sulfite is required for
ADC hydrogenation to increase the catalyst activity and
suppress production of maleate, though the mechanism of
sodium sulfite’s action is not well understood. A key advantage
of this approach for in vivo applications is that the reaction can
be performed in water. Metabolism of PHIP-polarized [1-13C]
fumarate has now been observed in lysed and healthy tumor
cells in vitro,[35,39] though in vivo imaging of cell death has not
been reported to date.
In this work, we report; (i) a cost-effective synthetic pathway
for high-yield production of [1-13C]acetylenedicarboxylic acid,
(ii) generation of HP [1-13C]fumarate using a simple hydro-
genative PHIP experimental set-up and the trans-selective Ru-
based catalyst, (iii) elucidation of the trans-selectivity of hydro-
genation with the Ru-based catalyst via density functional
theory (DFT) simulations, (iv) in vitro magnetic resonance
spectroscopy (MRS) of HP 13C malate generated from HP [1-13C]
fumarate in the mixture with liver homogenate, (v) the
feasibility of in vivo MRI of PHIP-polarized [1-13C]fumarate
metabolism for detection of cell necrosis in a murine acetami-
nophen-induced model of hepatitis, where the anti-inflamma-
tory agent acetaminophen is well known to cause necrotic cell
death in the liver that is often a problem in a clinical practice.
2. Results and Discussion
2.1. Synthesis of [1-13C]Acetylenedicarboxylic Acid
In general, in vivo MRI experiments involving hyperpolarized
13C-labeled tracers consume a much larger amount of the tracer
than in most in vitro NMR studies. Thus, for hydrogenative PHIP,
there is a great need for a low-cost, high-yield synthesis
pipeline for producing the hydrogenation precursor. Here, this
is [1-13C]acetylenedicarboxylic acid, which is available commer-
cially by special order, though costly. We developed a synthesis
pathway with [1-13C]sodium acetate as a starting material, as
described in Scheme 1, the Experimental Section and Support-
ing Information. The total yield of the final product was ~43%.
2.2. DFT Simulations of the Trans-selective Hydrogenation
Reaction of Acetylene Dicarboxylate
M. Leutzsch et al. analyzed the trans-selective hydrogenation of
2-butyne in CH2Cl2 using the [Cp*Ru(MeCN)3]PF6 catalyst using
DFT theory.[37] In the following calculation, we referred to the
Leutzsch’s mechanisms and analyzed the trans-hydrogenation
of acetylenedicarboxylate in water using the same catalyst at
the SMD/B3PW91/6-311+ +G(2df,2p)(C,H,N,O),DGDZVP(Ru)//
SMD/B3PW91/DGDZVP level of theory. We show a computed
energy diagram under basic conditions in Figure 1. This
diagram indicates relative energies for the reaction start point
A0. Values in parentheses are activation free energies from the
reactant or intermediate of each step in the direction of forward
reaction.
The first step of this reaction under basic conditions starts
from catalyst A0 to A3 via intermediate A1. A1 is a stable
complex with coordination of ADC and hydrogen gas shown in
Figure 2. ADC coordinates as a dianion and one carboxylate
interacts with the proton of the coordinated hydroxide ion by a
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Scheme 1. Four-step synthesis pathway for the [1-13C]fumarate precursor, [1-13C] acetylenedicarboxylic acid, using [1-13C]sodium acetate as a starting material.
Full details are provided in the Experimental Section and the Supporting Information.
Figure 1. Free energy diagram for the trans-selective hydrogenation reaction of acetylenedicarboxylate using [Cp*Ru(MeCN)3]PF6 at SMD/B3PW91/6-311+
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not have hydrogen bonds with the catalyst. A1 proceeds to an
active complex A2 and further to A3 with the transfer of a
hydrogen atom to the triple bond. The activation energy of the
step from A0 to A3 was computed as ΔG�=11.9 kcalmol 1.
After the formation of A3, the reaction proceeds to Z1 and turns
over and reach C2 (alkane) via a transition state C2_Z1TS
without any notable barrier. From C2, there are two reaction
routes. One is a route to trans-alkene E2 via C1 and E1 and the
other is a route to cis-alkene Z3 via Z1 and Z2. By considering
these routes as pseudo-one-step reactions (as intermediates C1
and Z1 are not stable), the rate determining ΔG � of these
routes are 21.5 and 24.5 kcalmol 1 at the transition states of
E1_C1TS and Z1_Z2TS, respectively. Based on Eyring’s absolute
reaction rates theory, the difference of activation free energies
ΔΔG�=3.0 kcalmol 1 gives a production ratio of trans and cis
alkene at 80 °C of 98.6 :1.4. Though the actual production ratio
will change depending on the concentration of substrate and
catalyst, energies of recovery cycles of the catalyst, pH, the
diffusion of hydrogen bubbles and so on, this simulation
suggests that the formation of trans-alkene is dominant in this
system and supports observed experimental results.
Under neutral conditions, the reaction proceeds with the
same mechanism as that of basic conditions and produces a
semi-stable C2. Figure 3 shows the free energy diagrams
leading to trans-alkene E2 and cis-alkene Z3 from C2 in neutral
and basic conditions comparatively. The rate determining ΔG�
of the routes to E2 and Z3 in neutral conditions were computed
as 30.9 and 33.5 kcalmol 1. ΔΔG�=2.6 kcalmol 1 is smaller
than the basic condition and it causes slight deterioration of
the selectivity. The production ratio in this condition at 80 °C
can be calculated as trans : cis=97.6 : 2.4. We can also calculate
the difference between basic and neutral reaction rates by the
Eyring’s equation. At 80 °C, normalizing to the reaction rate in
basic conditions (1.0), the relative rate in neutral conditions is
calculated as 1.5×10 6 to produce trans-alkene E2 and 2.7×
10 6 to cis-alkene Z3. Therefore, the reaction in neutral
conditions is orders of magnitude slower than that in basic
conditions, and thus considered difficult to proceed in the same
reaction time.
2.3. Parahydrogen Addition Reaction
[1-13C]fumarate concentrations of the order of 25 mM (hydro-
genation percentage ~10%) were obtained using the proce-
dures described in the Experimental Section. This is in
approximate agreement with that of Knecht et al who
employed an automated hydrogenation system (for a ~10 s
hydrogenation time; see Figure 2a of Ref. [39]). Crucially, this
concentration of fumarate is comparable to that used in the
original demonstration of in vivo MR imaging of necrosis using
dDNP-polarized fumarate (though in that study, doubly-labeled
[1,4-13C]fumarate was used, which leads to double the NMR
sensitivity for a given concentration).[15] Nevertheless, the
achievable [1-13C]fumarate concentration remains a major
limitation of our approach. The advent of fully-automated
apparatus and reaction chambers capable of withstanding gas
pressures exceeding 10 bar should lead to more efficient
hydrogenation and thus increased concentration and/or polar-
ization of [1-13C]fumarate doses for in vivo applications in the
near future. While automated set-ups are of course desirable,
Figure 2. An optimized structure of stable reactant complex of A1.
Figure 3. Comparative free energy diagram for the hydrogenation of acetylenedicarboxylic acid using [Cp*Ru(MeCN)3]PF6 in basic and neutral conditions from
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the manual procedure implemented here has advantages in
terms of minimization of the fluid path length and in-turn
potential losses of substrate volume or polarization (e.g.
through contact with paramagnetic impurities).
2.4. Spin Order Transfer
Trans-selective hydrogenation of [1-13C]ADC with the ruthe-
nium-based catalyst Cp*Ru(MeCN)3PF6 results in the production
of [1-13C]fumarate with two parahydrogen-derived hyperpolar-
ized 1H nuclei. Efficiency of spin order transfer from these
hyperpolarized 1H to the labeled 13C spin was investigated by
applying either INEPT-type spin order pulse sequences L-PH-
INEPT+ or S2hM using nested 1H and 13C RF coils in a 1.5T MRI
scanner, or a magnetic field cycling (MFC) approach using a
zero-field chamber. More than 12% (12 + / 2% over 4
measurements) 13C polarization at the time of the subsequent
13C NMR/MRI scan was achieved by MFC and S2hM with the
Cp*Ru(MeCN)3PF6 catalyst. While this polarization value is
reasonable, we believe there is still room for improvement. In
particular, Eills et al. recently reported 24% 13C-polarization of
fumarate by applying a constant adiabaticity magnetic field
cycle[35] and further improvement to >30% by a new
purification procedure,[39] but we have not yet succeeded to
reproduce their experiments. On the other hand, Korchak et al.
reported the feasibility of 20% 13C-polarization of acetate from
vinyl acetate as a precursor by using another INEPT-type SOP
sequence known as ESOTHERIC.[40] Based on the J-coupling
network, fumarate should be more efficiently polarized than
acetate. Collectively, it seems too early to conclude whether
MFC- or INEPT-type approaches are more efficient for polarizing
fumarate from our still primitive experimental setup.
2.5. In vitro MRS of [1-13C]Fumarate in Tissue Homogenates
In dDNP studies, hyperpolarized [1,4-13C2]fumarate has been
successfully used to detect necrotic cell death in various disease
models. To investigate whether hyperpolarized [1-13C]
fumarate prepared by PHIP works comparably as a cell death
imaging probe, hyperpolarized [1-13C]fumarate solution was
mixed with mouse liver homogenates. Time dependent gen-
eration of the typical doublet peak of [1-13C] and [4-13C]malate,
whose production itself is a biomarker of necrotic cell
membrane destruction, was observed at 181 ppm immediately
after infusion of HP [1-13C]fumarate (Figure 4). By virtue of the
fact that the enzymatic activity of fumarase does not require
any cofactors, the [1-13C] and [4-13C]malate signal lasted for up
to several minutes and became undetectable at a similar time-
point to that of the [1-13C]fumarate peak.
2.6. In vivo Imaging of [1-13C]fumarate Metabolism
The feasibility of in vivo cell death imaging using PHIP-polarized
[1-13C]fumarate was assessed using an acetaminophen-induced
hepatitis mouse model. Two-dimensional chemical shift imag-
ing (CSI) performed at 4 hours after intraperitoneal injection of
acetaminophen on a 1.5T MRI scanner showed the production
of hyperpolarized [1-13C] and [4-13C]malate in the liver region
(Figure 5a). Note: the [1-13C] and [4-13C]malate peaks were
inseparable in vivo (though sometimes observable as a shoulder
bump), because their 1.2 ppm chemical shift difference is much
smaller than the typical 13C spectral linewidth in vivo in our
permanent magnet-based MRI scanner (over 2 ppm). The
distribution of hyperpolarized [1-13C]fumarate at ~20 sec after
injection showed strong signal from the abdominal aorta
(Figure 5b), whereas that of [1-13C] and [4-13C]malate signal
exhibited localization in the liver. High signal intensity around
the abdominal aorta on the malate map may result from
contamination by the much more intense [1-13C]fumarate peak.
By normalizing the signal intensity of the malate peak to that of
the fumarate peak, a parametric map of the malate-to-fumarate
ratio was produced that more clearly showed the localized
production of the cell death marker malate in the liver with
acetaminophen-indued hepatitis.
In this in vivo experiment, the [Cp*Ru(CH3CN)3]PF6 catalyst
was removed by a metal trapping column filling a QuadraPure®
TU (Sigma-Aldrich Co. LLC.) (see Supporting Information),
however some unreacted ADC still remained in the injection
solution. Although we did not see any cytotoxic effects of ADC
in these preliminary in vivo experiments, complete removal of
Figure 4. a) Schematic of the conversion of [1-13C]fumarate into [1-13C] and
[4-13C]malate by fumarase. b) Dynamic 13C NMR spectra of hyperpolarized
[1-13C]fumarate at 176 ppm produced by MFC-based PHIP (left) and the
fitted signal decay (right). c) Generation of hyperpolarized [1-13C] and [4-13C]
malate at around 181 ppm by mixing hyperpolarized [1-13C]fumarate with
mouse liver homogenates in vitro (left) and signal kinetics of the [1-13C]
fumarate and [1-13C] and [4-13C]malate peaks fitted with a two-compartment
exchange model (yielding T1 ~80 s for fumarate) (right). Note: the “DC offset”
at the beginning of the purple curve suggests that considerable metabolic
exchange occurred prior to the acquisition; this prevented us from obtaining
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ADC is desirable for future studies. We note that Knecht et al
recently reported a promising fumarate purification method
based on precipitation as a solid in concentrated HCl, however
this method relies on the addition of concentrated fumarate to
encourage precipitation and thus may not be practicable for
in vivo application at present.[39]
3. Conclusions
With low-cost polarization hardware and rapid polarization
times, hydrogenative PHIP with Ru-based catalysts holds great
promise as a scalable route to clinical use of HP [1-13C]fumarate
as a probe of cellular necrosis. In this work, we have
investigated several aspects of the process of PHIP-induced
polarization of [1-13C]fumarate and its application in vitro and
in vivo. In particular, we have reported a cost-effective synthetic
pathway for high-yield production [1-13C]acetylenedicarboxylic
acid that should help facilitate dissemination of the technique.
In addition, we have demonstrated initial feasibility of in vivo
MRI of PHIP-polarized [1-13C]fumarate metabolism for detection
of cell necrosis in a mouse model of hepatitis. These findings
should facilitate further pre-clinical studies and represent key
first steps in the eventual clinical translation.
Experimental Section
Synthesis of [1-13C]Acetylenedicarboxylic Acid
Full details of the synthesis of the [1-13C]fumarate precursor, [1-13C]
acetylenedicarboxylic acid, along with NMR spectra of the reaction
intermediates and final product, are provided as Supporting
Information. Briefly, the following describes the four-step synthesis
procedure with [1-13C]sodium acetate as a starting material that
was followed in this work (see also Scheme 1).
(i): Sodium acetate-1-13C (1.66 g, 1 Eq, 20.0 mmol) was melted,
combined with CHCl3 (6.6 mL), PBr3 (2.71 g, 943 μL, 0.5 Eq,
10.0 mmol) and bromine (6.39 g, 2.06 mL, 2 Eq, 40.0 mmol) and
warmed to 55 °C. After stirring for 96 h at 55 °C, the reactants were
cooled to 0 °C and hexan-1-ol (5.11 g, 6.28 mL, 2.5 Eq, 50.0 mmol)
was added. The reactants were then stirred for 30 min at 25 °C,
poured into a solution of 1 M aqueous Na2SO3 and extracted with
hexane. The organic layers were washed with saturated NaHCO3,
dried over Na2SO4 and evaporated under vacuum. The residue was
purified by column chromatography on silica gel eluting with 0~
60% CH2Cl2 in hexane to give hexyl 2-bromoacetate-1-
13C (4.00 g,
17.8 mmol, 89%) as a colorless oil.
(ii): To a stirred solution of HMDS (1.01 g, 1.30 mL, 1 Eq, 6.25 mmol)
in THF (20 mL) was added n-BuLi (380 mg, 2.12 mL, 2.80 molar,
0.95 Eq, 5.93 mmol) at 0 °C under argon atmosphere. After stirring
for 10 min, the solution was cooled to  78 °C and ethyl 2-
(phenylselanyl)acetate (1.52 g, 1 Eq, 6.25 mmol) was added. After
stirring for 30 min at  78 °C, hexyl 2-bromoacetate-1-13C (1.40 g,
1 Eq, 6.25 mmol) was added and the reactants were warmed to
 25 °C over 3 h and quenched with saturated aqueous NH4Cl. The
organic layer was extracted with hexane, dried over Na2SO4 and
evaporated under vacuum. To the residue containing 1-ethyl 4-
hexyl 2-(phenylselanyl)succinate-4-13C, CH2Cl2 (10 mL) was added.
After cooling to 0 °C, mCPBA (3.32 g, 65% Wt, 2 Eq, 12.5 mmol) was
added and the reactants were stirred for 30 min at 0 °C, diluted
with hexane (50 mL) and filtrated through a pad of Celite. The
filtrate was evaporated under vacuum and the residue was purified
by column chromatography on silica gel eluting with AcOEt/hexane
0 to 4% to give ethyl hexyl fumarate-4-13C (1.13 g, 4.93 mmol, 79%)
as a pale-yellow oil.
(iii): Ethyl hexyl fumarate-4-13C (1.13 g, 1 Eq, 4.93 mmol) in CH2Cl2
(5 mL), AIBN (40.5 mg, 0.05 Eq, 246 μmol) and Br2 (945 mg, 305 μL,
1.2 Eq, 5.91 mmol) were combined in a flask and warmed to 40 °C.
After stirring for 24 h, the progress of the reaction was monitored
by TLC (Hex/CH2Cl2 1/1). AIBN (20.3 mg, 0.025 Eq, 123 μmol) was
added to the flask and the reaction was stirred for 24 h at 40 °C.
The reaction was quenched with 1 M aqueous Na2SO3, extracted
with CH2Cl2, dried over Na2SO4 and evaporated under vacuum. The
residue was purified by column chromatography on silica gel
eluting with CH2Cl2/hexane 5 to 50% to give 1-ethyl 4-hexyl 2,3-
dibromosuccinate-4-13C (1.77 g, 4.54 mmol, 92%, dr=83 :17) as a
colorless oil.
(iv): To a test tube containing KOH (2.52 g, 85% Wt, 9 Eq,
38.2 mmol) dissolved in water (3.8 mL) at 0 °C, 1-ethyl 4-hexyl 2,3-
dibromosuccinate-4-13C (1.65 g, 1 Eq, 4.24 mmol) dissolved in THF
(0.4 mL) was added and the reactants were stirred vigorously at
0 °C for 2 h. The solution was washed with hexane and the aqueous
phase was acidified with 12 N HCl (4 mL). The solution was washed
with toluene to remove impurities. The organic materials were then
extracted with AcOEt. The combined organic layers were dried over
Na2SO4 and evaporated under vacuum to give [1-
13C]
acetylenedicarboxylic acid (328 mg, 2.85 mmol, 67.2%, ~90%
purity as determined by 13C NMR).
DFT Simulations of Cp*Ru-catalyzed trans-Hydrogenation
It is known that a Cp*Ru-catalyzed trans-hydrogenation of
acetylenedicarboxylic acid in water is accelerated and the trans-
selectivity of the product is improved under basic conditions.[34] To
clarify this phenomenon, density functional theory calculations
were carried out and reaction mechanisms were analyzed.
B3PW91[41,42] functional and basis sets of 6-311G(d,p) and
Figure 5. In vivo CSI of hyperpolarized [1-13C]fumarate metabolism in an
acetaminophen-induced hepatitis mouse. a) Representative 13C NMR spec-
trum of hyperpolarized [1-13C]fumarate and its metabolite for a CSI pixel at
the liver. b) Map of hyperpolarized [1-13C]fumarate CSI signal intensity
overlaid on an anatomical 1H MRI image. c) Map of hyperpolarized [1-13C]
and [4-13C]malate. d) parametric map of the malate/fumarate ratio; a
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DGDZVP[43,44] for H, C, N, O atoms and Ru atom respectively were
applied for energies, and the DGDZVP basis set was applied for
optimizing geometries. The self-consistent reaction field (SCRF)
method with the Solvation Model based on Density (SMD) model[45]
was used to describe the aqueous solvent. As substrate complexes
for reactants and products, we searched for and adopted structures
that seemed to be the most stable. We searched transition states
structures with using the energy gradient method and confirmed
that they had only one imaginary frequency. In order to confirm
whether the transition states lead to products and reactants,
intrinsic reaction coordinate (IRC) calculations[46] were performed.
Vibration analyses at 298.15 K and 1 atm were executed for all
structures to calculate Gibbs correlation energies, hence reactions
were evaluated using relative Gibbs free energy. All calculations
were performed using Gaussian09.[47]
Parahydrogen Generation
Parahydrogen gas was generated using a home-built system based
on that described in reference.[48] Briefly, hydrogen gas was flowed
at 1–2 NL/min through a quarter inch copper tube containing iron
(III) oxide (371254-250G, Sigma-Aldrich, St Louis, MO) catalyst
wound on the 2nd stage of a Gifford-McMahon cryocooler
(Sumitomo Heavy Industries, Ltd., Tokyo, Japan) at 15–25 K and
housed within a cryostat-vacuum system (Thermal Block Company,
Saitama, Japan). Over time, the converted parahydrogen gas was
accumulated in a stainless-steel cylinder (either 316 L-HDF4-500,
500 cm3 or 304 L-HDF4-1GAL, 3785 cm3, Swagelok, Solon, OH) until
a pressure of 9–10 bar was obtained. This system reproducibly
yields a parahydrogen concentration of 90–95% with a lifetime of
the order of weeks in the storage cylinders, as quantified by a
benchtop Raman spectrometer (EZRaman, TSI Incorporated, MN)
with a 520 nm laser.
Parahydrogen Addition Reaction
Samples were prepared similarly to as described in references.[34,35,39]
Briefly, 3.78 mg of sodium sulfite (final 50 mM) was added to a
high-pressure glass vial and introduced into a glovebox under
argon atmosphere (<0.5% O2), and mixed with 596 μL D2O and
4 mg of [RuCp*(MeCN)3]PF6 (final 13.2 mM, #667412, Sigma-Aldrich,
St Louis, MO). The sample was then subjected to sonication for up
to 60 min, until the catalyst was completely dissolved (temperature
was gradually increased to 30–40 °C by this process). 3.45 mg of
[1-13C]acetylenedicarboxylic acid (final 50 mM) was added to the
catalyst solution, along with 4 μL of 40% NaOD. The pH of the final
solution was around 10.
The reaction vial was then removed from the glovebox and heated
for ~90 sec on a thermal block at 90 °C. The vial cap was replaced
with a custom cap connected to 1/16’’ OD PEEK tubing. Para-
hydrogen gas was injected at 8–10 bar, and the vial was manually
shaken for the duration of the parahydrogen exposure (either
10 sec or 60 sec), after which the gas source was closed, and the
gas pressure released prior to opening the vial.
After experiments, the reaction vials were rinsed with chloroform
and washed with 1 M HCl and 50 mM EDTA heated to 70 °C to
remove residual catalyst and other impurities. In a small subset of
samples that were not used for subsequent spin order transfer for
in vitro or in vivo 13C MR studies, the percentage of hydrogenation
was quantified by 1H NMR using a JEOL ECS400 C (Delta V5.0.4)
400 MHz NMR spectrometer.
Spin Order Transfer
Spin order transfer from 1H to 13C was induced using one of several
different methods, including magnetic field cycling (MFC)[49,50] and
RF pulse sequences; specifically, an INEPT-type RF pulse sequence
adapted for parahydrogen applications; longitudinal (l)-PH-INEPT +
,[51,52] and the recently-developed Singlet to heteronuclear Magnet-
isation (S2hM) sequence.[53] L-PH-INEPT+ and S2hM were imple-
mented on a home-built 1.5 T permanent magnet MRI system with
a Japan REDOX spectrometer (Japan REDOX Ltd., Fukuoka, Japan),
with timings determined from the J-couplings in [1-13C]fumarate,
assuming an AA’X system. Home-built 1H and 13C RF coils of saddle
or solenoid design were nested and utilized to play out the RF
sequences while a vial or syringe containing 1H-hyperpolarized
[1-13C]fumarate was placed inside the coil active region (immedi-
ately after the parahydrogenation reaction).
In MFC experiments, the vial containing 1H-hyperpolarized [1-13C]
fumarate after parahydrogen addition was rapidly inserted into a
zero-field chamber and either (i): (adiabatically) lifted out over the
course of a few seconds, (“manual”) approach; or (ii) subjected to
an electronically-controlled magnetic field sweep of bi-linear or
exponential time profile that adiabatically increased the field from
an initial zero field, (“automated”) approach. Both methods induced
sufficient spin order transfer from 1H to 13C. The zero-field chamber
comprised three μ-metal cylinders (ZG-206, Magnetic Shield
Corporation, Bensenville, IL) and was calibrated using a three-axis
magnetic field sensor (Mag 690–100, Bartington Instruments, Oxon,
UK) and three orthogonal field coils (an additional coil was used for
the electronic field sweep). Timings of the diabatic field demagnet-
ization and adiabatic remagnetization were optimized by a
combination of empirical experiments and density matrix simula-
tions based on the heteronuclear couplings between the [1-13C]
and parahydrogen nuclei in fumarate.[49,54]
In vivo Chemical Shift Imaging of [1-13C]Fumarate Metabolism
Ethical Statement for Animal Experiments
All animal experiments were performed under the ‘Law for The
Care and Welfare of Animals in Japan’ and were approved by the
Animal Experiment Committee of Hokkaido University (Approval
No.16-0058).
In vitro Tissue Homogenate Studies
MR spectroscopy was performed on either a 60 MHz benchtop NMR
system (NMReady-60 Pro, Nanalysis Corp., Canada), or a home-built
1.5 T permanent magnet MRI system with a multinuclear spectrom-
eter (Medalist, Japan REDOX Ltd). In vitro spectroscopic acquisitions
involved the dynamic acquisition of 13C spectra over a period of 3–
5 minutes until the [1-13C]fumarate signal became undetectable.
Typical parameters were as follows: TR 3 s; flip angle ~20 °; spectral
bandwidth ~200 ppm, centred on the [1-13C]fumarate resonance.
Liver tissue derived from healthy mice was homogenized and
placed into a standard NMR tube (NMReady system), or small
chemical vial (MRI system). HP [1-13C]fumarate was infused into the
homogenate mixture by injecting through 1/16’’ OD PTFE or PEEK
tubing from a syringe outside the magnet bore. Because it is
necessary to perform hydrogenation of [1-13C]ADC under basic
conditions, neutralization was required prior to injection into




921ChemPhysChem 2021, 22, 915–923 www.chemphyschem.org © 2021 The Authors. ChemPhysChem published by Wiley-VCH GmbH
In vivo Animal Studies
Female C3H/HeJYokSlc mice were obtained from Japan SLC Inc.
(Shizuoka, Japan) and instilled intraperitoneally with acetamino-
phen (200 mg/kg body weight) to induce a model of hepatitis. MR
spectroscopic imaging was performed at 4–6 hours after admin-
istration of acetaminophen. The 1.5 T permanent magnet MRI
system with a Japan REDOX spectrometer was used in combination
with home-built RF coils which consists of an inside solenoid coil
for 13C and an outside saddle coil for 1H channels. In vivo imaging
experiments were performed using a conventional 2D spatially
phase-encoded 13C chemical shift imaging (CSI) pulse sequence. Up
to 4 dynamic CSI datasets were acquired over a period of 2 minutes.
Typical parameters were set as follows: 16×16 matrix; FOV 32×
32 mm (in-plane spatial resolution 2×2 mm); slice thickness 20 mm;
TE/TR, 10/75 ms; flip angle ~20°; spectral bandwidth, 2 kHz. HP
[1-13C]fumarate was injected through the tail vein over the course
of 10 seconds, using a plastic cannula connected to a syringe
outside the magnet bore via 1/16’’ OD PTFE or PEEK tubing.
Immediately prior to injection, the [CpRu(CH3CN)3]PF6 catalyst was
removed by a column filled with a QuadraPure® TU (Sigma-Aldrich
Co. LLC.) metal scavenger resin (However, we note that some
unreacted ADC remained in the injected solution).
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